Flinton Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Flinton Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$694K	Sell	7,084 -476	-6%	-$53.7K	0.02%	377
2019 Q2	$990K	Sell	7,560 -2,576	-25%	-$332K	0.03%	324
2019 Q1	$1.37M	Buy	10,136 +2,492	+33%	+$310K	0.05%	252
2018 Q4	$744K	Sell	7,644 -140	-2%	-$16.5K	0.03%	326
2018 Q3	$1.08M	Buy	7,784 +84	+1%	+$10.5K	0.03%	306
2018 Q2	$956K	Buy	7,700 +1,036	+16%	+$121K	0.03%	314
2018 Q1	$743K	Sell	6,664 -280	-4%	-$33.5K	0.02%	335
2017 Q4	$831K	Buy	6,944 +1,932	+39%	+$235K	0.03%	323
2017 Q3	$703K	Sell	5,012 -896	-15%	-$122K	0.03%	329
2017 Q2	$719K	Buy	5,908 +476	+9%	+$55.4K	0.03%	313
2017 Q1	$658K	Buy	5,432 +840	+18%	+$108K	0.03%	319
2016 Q4	$562K	Buy	+4,592	New	+$562K	0.02%	313

Other funds holding ALXN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Flinton Capital Management's ALXN Position: Q3 2019 in Review

Flinton Capital Management reduced its Alexion Pharmaceuticals (ALXN) stake by 6.3% in Q3 2019, selling an estimated $53.7K and leaving 7,084 shares worth $694K. The position accounts for 0.02% of the portfolio, ranked #377.

Flinton Capital Management first reported a position in ALXN in Q4 2016 and has held it in 12 quarters since. The position peaked at $1.37M in Q1 2019. 646 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

Flinton Capital Management held 7,084 shares of Alexion Pharmaceuticals worth $694K as of Q3 2019.
Flinton Capital Management sold 476 Alexion Pharmaceuticals shares in Q3 2019, an estimated $53.7K.
Alexion Pharmaceuticals made up 0.02% of Flinton Capital Management's portfolio in Q3 2019, its #377 holding.
Flinton Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2016 and has held it in 12 quarters since.
Flinton Capital Management's Alexion Pharmaceuticals position peaked at $1.37M in Q1 2019.
646 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.